A study in Chile with 10.2 million participants assessed the effectiveness of the inactivated SARS-CoV-2 (CoronaVac) vaccine, developed in China. Efficacy among fully vaccinated subjects was estimated at 65.9% protection against symptomatic COVID-19. In contrast, there was 87.5% protection against hospitalization, 90.3% protection against ICU admission, and 86.3% protection against death as a result of COVID-19.
https://www.nejm.org/doi/full/10.1056/NEJMoa2107715